Chinese Regulator Approves Luye Pharma Group's New Drug for Marketing

MT Newswires Live07-04

Luye Pharma Group's (HKG:2186) new analgesic product Mimeixin was approved for marketing on June 28, by the National Medical Products Administration of China, for pain management purposes, a Thursday filing with the Hong Kong Exchange said.

Mimeixin is an oral sustained-release tablet combined with oxycodone and naloxone, used for severe pain management in adults where only opioids are known to work. The new drug, as an additional advantage, also reduces opioid-induced constipation by blocking the binding of oxycodone to opioid receptors in the intestines.

The tablet has also been proven effective for pain management in cases other than cancer-induced pain, including musculoskeletal pain, postoperative pain, and lower back pain among others.

The new drug also uses proprietary drug-locking technology deterring drug abuse. The tablet also prevents any euphoric sensations to the users, further reducing the risk of abuse.

The company's shares were up 1% on Thursday's close.

Price (HKD): $2.82, Change: $+0.03, Percent Change: +1.08%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2448252514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-04 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2448252514","market":"nz","top_or_hot":-1,"title":"Chinese Regulator Approves Luye Pharma Group's New Drug for Marketing","media":"MT Newswires Live","content":"<html><body><p> Luye Pharma Group's (HKG:2186) new analgesic product Mimeixin was approved for marketing on June 28, by the National Medical Products Administration of China, for pain management purposes, a Thursday filing with the Hong Kong Exchange said.</p><p>Mimeixin is an oral sustained-release tablet combined with oxycodone and naloxone, used for severe pain management in adults where only opioids are known to work. The new drug, as an additional advantage, also reduces opioid-induced constipation by blocking the binding of oxycodone to opioid receptors in the intestines.</p><p>The tablet has also been proven effective for pain management in cases other than cancer-induced pain, including musculoskeletal pain, postoperative pain, and lower back pain among others.</p><p>The new drug also uses proprietary drug-locking technology deterring drug abuse. The tablet also prevents any euphoric sensations to the users, further reducing the risk of abuse.</p><p>The company's shares were up 1% on Thursday's close.</p><p>Price (HKD): $2.82, Change: $+0.03, Percent Change: +1.08%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Regulator Approves Luye Pharma Group's New Drug for Marketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Regulator Approves Luye Pharma Group's New Drug for Marketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-04 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Luye Pharma Group's (HKG:2186) new analgesic product Mimeixin was approved for marketing on June 28, by the National Medical Products Administration of China, for pain management purposes, a Thursday ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2448252514","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448252514","pubTimestamp":1720101613,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Luye Pharma Group's  new analgesic product Mimeixin was approved for marketing on June 28, by the National Medical Products Administration of China, for pain management purposes, a Thursday filing with the Hong Kong Exchange said.Mimeixin is an oral sustained-release tablet combined with oxycodone and naloxone, used for severe pain management in adults where only opioids are known to work. The new drug, as an additional advantage, also reduces opioid-induced constipation by blocking the binding of oxycodone to opioid receptors in the intestines.The tablet has also been proven effective for pain management in cases other than cancer-induced pain, including musculoskeletal pain, postoperative pain, and lower back pain among others.The new drug also uses proprietary drug-locking technology deterring drug abuse. The tablet also prevents any euphoric sensations to the users, further reducing the risk of abuse.The company's shares were up 1% on Thursday's close.Price : $2.82, Change: $+0.03,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1606":"中医药概念","BK1191":"制药","BK4526":"热门中概股","BK4588":"碎股","BK1583":"高瓴概念","BK4023":"应用软件","02186":"绿叶制药","HKD":"尚乘数科"},"translate_title":"中国监管机构批准绿叶制药集团新药上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"02186":0.9},"content_text":"Luye Pharma Group's (HKG:2186) new analgesic product Mimeixin was approved for marketing on June 28, by the National Medical Products Administration of China, for pain management purposes, a Thursday filing with the Hong Kong Exchange said.Mimeixin is an oral sustained-release tablet combined with oxycodone and naloxone, used for severe pain management in adults where only opioids are known to work. The new drug, as an additional advantage, also reduces opioid-induced constipation by blocking the binding of oxycodone to opioid receptors in the intestines.The tablet has also been proven effective for pain management in cases other than cancer-induced pain, including musculoskeletal pain, postoperative pain, and lower back pain among others.The new drug also uses proprietary drug-locking technology deterring drug abuse. The tablet also prevents any euphoric sensations to the users, further reducing the risk of abuse.The company's shares were up 1% on Thursday's close.Price (HKD): $2.82, Change: $+0.03, Percent Change: +1.08%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448252514"}